Trintellix patent expiration date?

What triggers the impending patent expiration for Trintellix?

Trintellix (vortioxetine) is an antidepressant medication developed by Takeda Pharmaceuticals and Lundbeck. The drug's patent protection is set to expire, allowing for the introduction of generic versions.

When does Trintellix's exclusivity expire?

According to the data available on DrugPatentWatch.com [1], the patent for Trintellix is set to expire in the United States on March 29, 2028. This expiration date marks the end of the patent's exclusive market period, allowing generic manufacturers to produce similar versions of the medication.

Impact on Trintellix sales and patient access

As the patent expires, generic versions of Trintellix are expected to enter the market, potentially increasing patient access to the medication and reducing prices. This development could also impact sales for the original branded version of the medication.

Current market situation and competitor landscape

The market for antidepressants is highly competitive, with established players like Eli Lilly's Prozac and Pfizer's Zoloft. As generic versions of Trintellix become available, these competitors may face increased competition and pressure on their pricing and market share.

Sources:

[1] https://www.drugpatentwatch.com/drug/Trintellix (accessed on May 26, 2024)

Sources:

1. DrugPatentWatch.com